Tech Center 1600 • Art Units: 1615 1644
This examiner grants 43% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 17798262 | RADIOLABELED FIBRONECTIN BASED SCAFFOLDS AND ANTIBODIES AND THERANOSTIC USES THEREOF | Non-Final OA | BRISTOL-MYERS SQUIBB COMPANY |
| 17630837 | IMMUNITY INDUCER AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING AGING-RELATED DISEASES | Non-Final OA | Juntendo Educational Foundation |
| 18003462 | GROWTH AND SITE-SPECIFIC ORGANIZATION OF MICRO-SCALE BIMOLECULAR DEVICES ON LIVING CELLS | Non-Final OA | The Johns Hopkins University |
| 18713834 | HAIR TREATMENT METHOD | Non-Final OA | KAO CORPORATION |
| 17160750 | EYELASH COMPOSITIONS CONTAINING SUGAR | Non-Final OA | L'OREAL |
| 17918377 | METHOD OF LONG-TERM PRESERVATION OF CHEMICAL AND BIOLOGICAL SPECIES USING SUGAR GLASSES | Non-Final OA | McMaster University |
| 18724716 | Oral Care Compositions and Methods for the Same | Non-Final OA | Colgate-Palmolive Company |
| 18675021 | PEEL-OFF LIP LINER STAIN | Non-Final OA | Sacheu Beauty Inc. |
| 17998141 | CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | Non-Final OA | Ionis Pharmaceuticals, Inc. |
| 18016165 | THERAPEUTIC USE OF GLUCAGON DERIVATIVE OR CONJUGATE THEREOF FOR LIVER DISEASE | Final Rejection | HANMI PHARM. CO., LTD. |
| 17926912 | LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON, GLP-1, AND GIP TRIGONAL AGONIST | Final Rejection | HANMI PHARM, CO., LTD. |
| 18017179 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING DYSTROPHINOPATHIES | Final Rejection | Dyne Therapeutics, Inc. |
| 18017182 | MUSCLE-TARGETING COMPLEXES AND USES THEREOF IN TREATING MUSCLE ATROPHY | Non-Final OA | Dyne Therapeutics, Inc. |
| 18005900 | METHODS AND COMPOSITIONS FOR INCREASING IMMUNITY AGAINST CORONAVIRUSES | Non-Final OA | LEYDEN LABORATORIES B.V. |
| 18009601 | FUSION PROTEIN CONTAINING ERYTHROPOIETIN POLYPEPTIDE | Non-Final OA | BICA THERAPEUTICS INC. |
| 17906956 | METHOD FOR CREATING MULTIMERIC IgA ANTIBODY, AND MULTISPECIFIC MULTIMERIC IgA ANTIBODY | Non-Final OA | JAPAN as represented by DIRECTOR GENERAL of National Institute of Infectious Diseases |
| 17640544 | ANTI-STEM CELL FACTOR ANTIBODIES AND METHODS OF USE THEREOF IN RENAL DISEASE | Non-Final OA | Opsidio, LLC |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy